Outsourced Production Fuels Antibody-Drug Conjugate Growth
Biotech firms increasingly rely on external manufacturing to navigate the high-containment demands of ADCs.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you believe outsourcing drug manufacturing makes advanced medical treatments more accessible to patients?
The global market for antibody-drug conjugates (ADCs) is expanding rapidly, with 70 to 80 percent of development currently outsourced. This shift helps biotech companies manage the complex production requirements inherent in these specialized therapies.
Why it matters
ADCs integrate antibody engineering, linker synthesis, and cytotoxic payload handling, requiring highly specialized infrastructure. Outsourcing allows developers to bypass the significant capital investment needed for compliant, high-containment manufacturing.
The global ADC market reached 14.75 billion in 2024, with more than 200 clinical-stage programs active by 2025. The market is projected to reach approximately 36 billion by 2034.
The details
Manufacturing an ADC involves integrating an antibody, a chemical linker, and a cytotoxic—cell-killing—payload. Developers often employ site-specific conjugation, a process that attaches payloads to precise locations on the antibody to ensure a uniform final product. High-potency active pharmaceutical ingredients within these constructs necessitate specialized high-containment infrastructure to protect workers and the environment.
Timeline
2024: The global ADC market value reached 14.75 billion.
2025: More than 200 clinical-stage ADC programs were identified.
2034: The global ADC market is projected to hit 36 billion.
The Tech Race
The reliance on external manufacturing mirrors the broader biotech industry's move toward contract development and manufacturing organizations to scale complex modalities. This trend signals an intensifying competition to secure capacity for the 200-plus clinical programs currently in development.
The scaling of ADC production via outsourcing is intended to accelerate the delivery of clinical-stage candidates to patients. Biotech firms now prioritize partners that can concurrently handle antibody production, linker-payload chemistry, and formulation.
The takeaway
The move toward outsourcing in ADC development serves as a primary indicator of the industry's need for standardized, high-containment production. Stakeholders should track the growth of the contract manufacturing pipeline through 2034 to gauge the velocity of new drug approvals.
Further reading
For more on how specialized manufacturing infrastructure shapes current drug development, see the Biotech section.
Source note: This article includes information reported by Pharmafocusasia.
Live Poll
Do you believe outsourcing drug manufacturing makes advanced medical treatments more accessible to patients?
